Living Cell Technologies : Chairman Presentation

ersonal use only

Chairman's Presentation to Extraordinary General Meeting

Professor Bernard Tuch

29 November 2021

www.lctglobal.com

Safe Harbour Statement

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results
only	to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities'
	requirements regarding any one or more product candidates nor can there be any assurance that such product candidates
	will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.
In particular, management's expectations regarding the approval and commercialization of the product candidates could be
use	affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and
new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or
ersonal	maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and
general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products,
product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward- looking statements contained in this document as a result of new information, future events or developments or otherwise.

ersonal use only

Where Proceeds of Raisings Will be Directed

ersonal use only

LCT's Cash Position Post Raisings

Financial ramifications of 2Q FY2021 raisings

• LCT to receive up to up to $7.3m (before costs) from 2Q FY2021 raisings
• Proforma cash position post raisings of $7.6 million

Where this additional capital will be directed

• Ongoing development of NTCELL treatment for Parkinson's disease
• Exploring the potential for treating other medical disorders with living cells

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |

LCTglobal

ersonal use only

ASX:LCT | OTCQB: LVCLY | www.lctglobal.com |

LCTglobal